Key Points
- CFO Adam Laponis sold 2,462 Twist Bioscience shares at an average price of $156.30, totaling $384,810.60. The sale covered tax-withholding obligations tied to vested equity awards, leaving him with 98,114 shares.
- Twist Bioscience reported quarterly revenue of $118.38 million, up 23.2% year over year, but missed EPS expectations with a loss of $0.56 per share versus the $0.51 consensus estimate.
- Analyst sentiment is mixed: eight analysts rate the stock a Buy, three a Hold and two a Sell, producing an overall “Hold” consensus and an average price target of $143.67.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 2,462 shares of the business's stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $156.30, for a total value of $384,810.60. Following the sale, the chief financial officer directly owned 98,114 shares of the company's stock, valued at $15,335,218.20. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Adam Laponis also recently made the following trade(s):
- On Friday, October 2nd, Adam Laponis sold 8,057 shares of Twist Bioscience stock. The stock was sold at an average price of $188.88, for a total value of $1,521,806.16.
Twist Bioscience Stock Performance
Shares of Twist Bioscience stock opened at $151.33 on Wednesday. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $219.71. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average price of $146.38 and a 200-day moving average price of $98.22. The company has a market cap of $9.49 billion, a PE ratio of -68.17 and a beta of 2.19.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to analysts' expectations of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm's quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.33 EPS. Equities analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
TWST has been the topic of several recent analyst reports. Evercore cut Twist Bioscience from an "outperform" rating to an "in-line" rating and set a $102.00 price objective on the stock. in a research note on Monday, July 6th. Barclays lifted their price objective on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Jefferies Financial Group initiated coverage on shares of Twist Bioscience in a report on Thursday, October 8th. They issued a "hold" rating and a $150.00 target price for the company. Canaccord Genuity Group raised their price target on shares of Twist Bioscience from $120.00 to $205.00 and gave the company a "buy" rating in a research report on Monday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research report on Monday, September 21st. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $143.67.
Check Out Our Latest Research Report on TWST
Hedge Funds Weigh In On Twist Bioscience
A number of hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC raised its holdings in Twist Bioscience by 24.4% during the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company's stock valued at $97,000 after buying an additional 185 shares during the last quarter. Allworth Financial LP boosted its position in Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company's stock valued at $62,000 after buying an additional 213 shares during the period. PNC Financial Services Group Inc. boosted its position in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company's stock valued at $46,000 after buying an additional 453 shares during the period. Trifecta Capital Advisors LLC purchased a new stake in Twist Bioscience during the 2nd quarter valued at $63,000. Finally, Western Wealth Management LLC bought a new stake in Twist Bioscience in the 1st quarter worth $31,000.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.
The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
